Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Aug 7, 2019
Date Accepted: Oct 23, 2019

The final, peer-reviewed published version of this preprint can be found here:

A Chatbot Versus Physicians to Provide Information for Patients With Breast Cancer: Blind, Randomized Controlled Noninferiority Trial

Bibault JE, Chaix B, Guillemassé A, Cousin S, Escande A, Perrin M, Pienkowski A, Delamon G, Nectoux P, Brouard B

A Chatbot Versus Physicians to Provide Information for Patients With Breast Cancer: Blind, Randomized Controlled Noninferiority Trial

J Med Internet Res 2019;21(11):e15787

DOI: 10.2196/15787

PMID: 31774408

PMCID: 6906616

Artificial Intelligence vs Physicians for Breast Cancer Patients' Information: a blind, randomized controlled non-inferiority trial

  • Jean-Emmanuel Bibault; 
  • Benjamin Chaix; 
  • Arthur Guillemassé; 
  • Sophie Cousin; 
  • Alexandre Escande; 
  • Morgane Perrin; 
  • Arthur Pienkowski; 
  • Guillaume Delamon; 
  • Pierre Nectoux; 
  • Benoit Brouard

ABSTRACT

Background:

The data regarding the use of conversational agents in oncology are scarce. INCASE is a non-inferiority randomized, controlled, blind trial that compared the information given by the Vik chatbot vs a multidisciplinary group of physicians to breast cancer patients. Patients were women with breast cancer in treatment or in remission.

Objective:

The aim of the INCASE study was to verify whether a conversational agent was able to provide answers to breast cancer patients with a level of satisfaction similar to the answers given by a group of physicians.

Methods:

The EORTC QLQ-INFO25 questionnaire was adapted and used to compare the quality of the information provided to patients by the physician or the chatbot. The primary outcome was to show that the answers given by the Vik chatbot to common questions asked by breast cancer patients about their therapeutic management are at least as satisfying as answers given by a multidisciplinary medical committee. The secondary objective was to compare for each INFO25 item the average scores obtained by the chatbot and by the physicians.

Results:

A total of 142 patients were included and randomized into two groups of 71. They were all female with a mean age of 42 years (SD 19). The answers provided by the group of physician's received an average rating of 2.82, while patients assessing Vik's answers gave an average rating of 2.89. The difference between success rates in the physicians’ group and Vik’s group was -0.03 (95% CI [-0.07; 0.00]). The binomial test showed the non-inferiority (p < 1e-14) of the chatbot’s answers.

Conclusions:

This is the first study that rigorously assessed a conversational agent used to inform cancer patients. The EORTC INFO25 scores from the chatbot were found to be non-inferior to the scores of the physicians. Conversational agents may save patients with minor health concerns from a visit to the doctor. This could allow clinicians to spend more time to treat patients who need a consultation the most. Clinical Trial: registered in the ClinicalTrials.gov database (NCT03556813)


 Citation

Please cite as:

Bibault JE, Chaix B, Guillemassé A, Cousin S, Escande A, Perrin M, Pienkowski A, Delamon G, Nectoux P, Brouard B

A Chatbot Versus Physicians to Provide Information for Patients With Breast Cancer: Blind, Randomized Controlled Noninferiority Trial

J Med Internet Res 2019;21(11):e15787

DOI: 10.2196/15787

PMID: 31774408

PMCID: 6906616

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.